Thermo Fisher Scientific is acquiring Patheon, which has been at the center of the consolidation that has swept through contract manufacturing in recent years, in a …
So what is the impact for Thermo, Patheon, and the pharma outsourcing market? Patheon has merged with Royal DSM's pharmaceutical products business to form DPx in a $2.65bn (€1.9bn) deal that analysts believe has created the world's second biggest CMO. Thermo Fisher Scientific Inc. is the world leader in serving science with revenues of $ 20 Billion and 65.000 employees in 50 countries.
Kim Speight-Campanella Senior Manager, Portfolio Services at Patheon, Part of Thermo Fisher Scientific Greenville, North Carolina 376 connections
Thermo Fisher's plan to buy Patheon pushed DSM shares to an all-time high of 67.92 euros on Monday. Further information is available at www.patheon.com.
DSM shares were up 2.64 pct at 1214 GMT. It was founded in 1974 as … Thermo Fisher Scientific has completed its $7.2-billion acquisition of Patheon. Der US-Laborausrüster Thermo Fisher will sein Geschäft mit einer milliardenschweren Übernahme ausbauen. Dutch food supplement maker DSM will tender its stake in U.S. drug ingredient maker Patheon to Thermo Fisher Scientific , DSM said on Monday.... | May 15, 2017
Thermo Fisher will also assume about $2 billion of net debt. Thermo Fisher Completes $7.2B Patheon Acquisition. Patheon and DSM complete $2.65bn merger to form private company 'DPx' By Dan Stanton 12-Mar-2014 - Last updated on 19-Aug-2019 at 10:10 GMT . Thermo Fisher's plan to buy Patheon pushed DSM shares to an all-time high of 67.92 euros on Monday.
On August 29, 2017, Thermo Fisher Scientific completed its acquisition of Patheon … Patheon shareholders will receive $35 in cash per share, representing a 35% premium from Friday's closing price of $26. DSM has entered into a tender and support agreement with Thermo Fisher pursuant to which DSM will tender its shares in the transaction.
The company needs a minimum of 80% of the shares under Dutch tender rules. 15.05.2017 In 2015, Patheon acquired Agere Pharmaceuticals, an Oregon company specializing in drug solubility, and IRIX, a maker of specialist Active Pharmaceutical Ingredients in South Carolina, the latter for $162.78 million. that their boards of directors have approved Thermo Fisher’s acquisition of Patheon.
Aug 29, 2017 | staff reporter.
Thermo Fisher has acquired all the shares of Patheon held by DSM for $35.00 per ordinary share in cash, resulting in a transaction payment to DSM of approximately $1.7 billion in cash. Our mission is to enable our customers to make our world healthier, cleaner and safer. To complete the deal, Thermo Fisher reached independent agreements with Patheon’s two largest shareholders — JLL Partners and Royal DSM, which hold nearly three-quarters of Patheon’s shares. DSM shares were up 2.64 pct at 1214 GMT. Durham-based Patheon N.V., a global provider of pharmaceutical development and manufacturing services that has a large production facility in Greenville, will be acquired by Thermo Fisher Scientific in a deal worth about $5.2 billion.. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transaction represents a purchase price …
Related tags: Chemical industry. DSM shares were up 2.64 pct at 1214 GMT. Thermo Fisher paid $35 a share for Patheon, a sum that amounts to about $5.2 billion, and assumed another $2 billion in debt for the Durham, North Carolina-based CDMO. NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today it has completed its $7.2 billion acquisition of contract development and manufacturing organization (CDMO) Patheon. Patheon N.V. is a pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Amsterdam and Durham, North Carolina, United States.It provides contract development and manufacturing services of prescription and over-the-counter pharmaceutical products for approximately 400 pharmaceutical and biotechnology companies..